FDA
-
-
-
-
-
-
-
Rhythm Pharmaceuticals reports positive Phase 2 data for PWS treatment
-
-
-
-
-
-
-
Rhythm Pharmaceuticals Announces Participation in Upcoming Investor Conferences
-
-
-
-
-
-
-
These are the best biotech stocks to own in 2026: BofA
-
-
-
-
-
-
-
Rhythm Pharmaceuticals (RYTM) PT Raised to $105 at H.C. Wainwright
-
-
-
-
-
-
-
Rhythm Pharmaceuticals reports expanded trial data for obesity drug
-
-
-
-
-
-
-
Rhythm Pharmaceuticals Announces Preliminary, Unaudited Fourth Quarter and Full Year 2025 Net Product Revenues and Upcoming Milestones
-
-
-
-
-
-
-
Rhythm Pharmaceuticals faces FDA review delay for obesity drug
-
325,297 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

